HCW Biologics’ HCW11‑040 immunotherapy abstract earns top‑150 placement at SITC meeting
HCW Biologics announced that its preclinical data on the tetravalent pembrolizumab‑based candidate HCW11‑040 was accepted among the 150 most notable abstracts out of 1,200 submissions for the Society for Immunotherapy of Cancer’s 41st annual conference. The company presented the findings on Saturday in Phoenix, highlighting that HCW11‑040 blocks PD‑1/PD‑L1 as effectively as pembrolizumab and surpasses it in reviving exhausted T cells. Its mouse analogue, HCW11‑050, also showed stronger activity against solid tumours in animal models. The presentation underscores the firm’s focus on fusion immunotherapeutics for cancer and other inflammation‑driven conditions.
Why it matters
The acceptance signals peer‑recognition of HCW Biologics’ platform, which may attract partnership interest and support future financing. Investors should note that the data are preclinical; any commercial impact depends on successful clinical translation.
Key facts
- 1HCW11‑040 was chosen as one of the 150 leading abstracts from a pool of 1,200 submissions for the 41st SITC annual meeting. stocktitan.net
- 2The abstract will be presented on Saturday, November 7, during the poster session in Phoenix, Arizona. stocktitan.net
- 3HCW11‑040 blocks the PD‑1/PD‑L1 interaction at a level comparable to pembrolizumab. investing.com
- 4In preclinical tests, HCW11‑040 outperformed pembrolizumab in reactivating exhausted T cells against human cancer cells. investing.com
- 5The mouse version, HCW11‑050, demonstrated superior anti‑solid‑tumor activity and promoted T‑cell infiltration in cold‑tumor models. investing.com
- 6HCW Biologics has signed two exclusive worldwide licensing agreements for some of its proprietary molecules. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.